SecBot SecBot

AGEN drug pipeline

AGENUS INC · 2 rated drugs
$6.29
−6.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
1
0 with results posted

Upcoming catalysts

1 dated
  1. Dec 2026
    Evamplix
    Phase 2 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 3
Time to marketAt least 3-5 years if Phase 3 BATTMAN succeeds; accelerated approval pathway was denied by FDA

botensilimab Updated Jul 13

What to watch

Agenus just announced a heavily dilutive ~$85M PIPE at $3.69/share to fund the Phase 3 BATTMAN trial, the stock is likely to trade under pressure from the overhang. Near-term upside depends on Phase 2 data catalysts (ASCO/ESMO presentations) and potential partnership deals, not regulatory approvals. The ~14.4% short interest adds squeeze risk on positive data surprises, but the fundamental path to commercialization is years away.

Bull case
  • Botensilimab has demonstrated durable survival benefit in MSS colorectal cancer, a historically immunotherapy-resistant population, 42% two-year survival reported July 2025 and 33% three-year survival reported June 2026 from the Phase 1b study (source: investor.agenusbio.com).
  • The Fc-enhanced mechanism is differentiated from Yervoy (ipilimumab), enabling Treg depletion in the tumor microenvironment. Preclinical and clinical data suggest broader activity than first-generation CTLA-4 antibodies (source: aacrjournals.org).
  • Analyst consensus is heavily bullish, 7 buy/strong-buy ratings vs 1 hold, with a mean price target of $15.50 (362% implied upside from $3.35) as of July 2026.
Bear case
  • The FDA advised against filing for accelerated approval of BOT/BAL in MSS colorectal cancer after the EOP2 meeting, stating that phase 2 ORRs may not translate to a survival benefit, forcing a long, expensive Phase 3 path (source: targetedonc.com).
  • Agenus just completed a massively dilutive ~$85M PIPE at $3.69/share, roughly 61% of the pre-offering market cap, with additional warrant overhang (Series A at $4.02 strike, Series B at $5.03 strike) that will pressure the stock (source: SEC 8-K filed July 13, 2026).
  • Short interest is elevated at ~14.4% of estimated shares outstanding (5.42 days to cover) and rising (+25.5% in the latest semi-monthly period), reflecting bearish conviction about the prolonged regulatory timeline and dilution (source: FINRA short positions data, settlement date June 30, 2026).
● neutral
Impact
PhaseApproved (Armenia only); Phase 3 (US/EU)
Time to marketApproved in Armenia (conditional, one-year authorization). No FDA or EMA approval timeline has been announced; the Phase 3 ROBBIN trial is expected to begin dosing in Q1 2027, meaning a potential US/EU approval, if successful, is likely several years away.

Evamplix balstilimab Updated Nov 7

What to watch

The next major catalyst is the start of the Phase 3 ROBBIN trial (first patient dosing expected Q1 2027), not a near-term binary event. The Armenia approval is a commercial milestone but not material for a US-listed stock. Watch for any FDA/EMA regulatory submission announcements or partnership deals, which could be share-price catalysts. The stock has already rallied ~195% YTD, reflecting optimism around BOT+BAL data.

Bull case
  • Strong clinical data: Phase 1b C-800-01 trial showed more than half of refractory MSS mCRC patients achieved long-term survival (SITC 2026). At ESMO 2026, 72% of dMMR colon cancer patients had no detectable cancer at surgery after six weeks of BOT+BAL in the Phase 2 NEOASIS study.
  • Analyst consensus is overwhelmingly bullish: 8 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $26.33 (268% upside from the $7.15 close). HC Wainwright and Chardan Capital maintain Buy ratings.
  • Major institutional accumulation in Q2 2026: BlackRock doubled its position to 2.56M shares, Goldman Sachs added 1,325%, and Vanguard, Geode, and State Street all significantly increased holdings.
Bear case
  • The Armenia approval is conditional and valid for only one year in a very small market, providing negligible commercial revenue. The drug remains unapproved by the FDA or EMA with no announced submission timeline.
  • The Phase 3 ROBBIN trial has not yet started enrolling (first patient expected Q1 2027), meaning a pivotal readout is likely years away. The company is a single-asset story dependent on BOT+BAL.
  • The PD-1 inhibitor market is intensely competitive, dominated by Merck's Keytruda and Bristol Myers' Opdivo. Balstilimab would need to demonstrate clear differentiation to gain meaningful market share.

Clinical trials

7 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
EvamplixVorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersPhase 2Active not recruiting107Dec 2026
EvamplixBotensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal AdenocarcinomaPhase 3Terminated21Jul 13, 2026
botensilimabA Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaPhase 2Terminated150Apr 27, 2026
botensilimabA Study of Botensilimab in Participants With Metastatic Pancreatic CancerPhase 2Completed81Jan 5, 2026
EvamplixRaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerPhase 2Terminated211Mar 26, 2025
botensilimabCombination Immunotherapy in Colorectal CancerPhase 2Completed · results26Nov 14, 2024
EvamplixA Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)Phase 2Completed · results175Jul 15, 2022